Proinflammatory events in right ventricular damage during pulmonary embolism: Effects of treatment with ketorolac in rats

John A. Watts, Michael A. Gellar, Lori K. Stuart, Maria Obraztsova, Jeffrey A. Kline

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Right ventricular (RV) damage contributes to poor clinical outcome after pulmonary embolism (PE). Our studies show that neutrophils contribute to RV dysfunction in rat PE. Present studies examine effects of the nonsteroidal anti-inflammatory drug, ketorolac, upon RV inflammation and dysfunction. RV inflammatory gene expression significantly increased 6 and 18 hours after PE [cytokine-induced neutrophil chemoattractant-1 (CINC-1) 18-fold and 24-fold; cyclooxygenase-2 21-fold and 32-fold]. Eighteen hours after PE, there was significant upregulation of adhesion molecules (selectin E 18-fold; intercellular adhesion molecule 1 14-fold), influx of neutrophils (myeloperoxidase activity 21-fold), depressed RV function (RV peak systolic pressure = 24 ± 3 vs. 40 ± 1 mm Hg; maximum rate of pressure development = 444 ± 79 vs. 1533 ± 146; maximum rate of pressure decrease = -357 ± 50 vs. -651 ± 44), and release of cardiac troponin I (7.8 ± 1.9 ng/mL) compared with vehicle. Ketorolac (10 mg/kg, intraperitoneally) significantly reduced expression of CINC-1, cyclooxygenase-2, selectin E, and intercellular adhesion molecule 1, lowered neutrophil influx, improved RV function (RV peak systolic pressure was 34 ± 3 mm Hg; maximum rate of pressure development = 1288 ± 146; maximum rate of pressure decrease = -611 ± 92), and marginally reduced cardiac troponin I release (P < 0.07) compared with PE alone. Ketorolac reduced CINC-1 stimulated chemotaxis of isolated neutrophils. PE converted cardiac tissue into a proinflammatory phenotype. Ketorolac reduced RV inflammatory genes, reduced neutrophil influx, and improved RV function in rat PE.

Original languageEnglish (US)
Pages (from-to)246-252
Number of pages7
JournalJournal of cardiovascular pharmacology
Volume54
Issue number3
DOIs
StatePublished - Sep 1 2009

Fingerprint

Ketorolac
Pulmonary Embolism
Neutrophils
Right Ventricular Function
Chemotactic Factors
Right Ventricular Dysfunction
Pressure
Troponin I
E-Selectin
Intercellular Adhesion Molecule-1
Cyclooxygenase 2
Cytokines
Blood Pressure
Chemotaxis
Peroxidase
Anti-Inflammatory Agents
Up-Regulation
Inflammation
Phenotype
Gene Expression

Keywords

  • Cyclooxygenase
  • Inflammation
  • NSAID
  • Neutrophils
  • Pulmonary embolism
  • Right ventricle

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Proinflammatory events in right ventricular damage during pulmonary embolism : Effects of treatment with ketorolac in rats. / Watts, John A.; Gellar, Michael A.; Stuart, Lori K.; Obraztsova, Maria; Kline, Jeffrey A.

In: Journal of cardiovascular pharmacology, Vol. 54, No. 3, 01.09.2009, p. 246-252.

Research output: Contribution to journalArticle

@article{ed4dea2e1d7c4d4881c27b73e1a3eca2,
title = "Proinflammatory events in right ventricular damage during pulmonary embolism: Effects of treatment with ketorolac in rats",
abstract = "Right ventricular (RV) damage contributes to poor clinical outcome after pulmonary embolism (PE). Our studies show that neutrophils contribute to RV dysfunction in rat PE. Present studies examine effects of the nonsteroidal anti-inflammatory drug, ketorolac, upon RV inflammation and dysfunction. RV inflammatory gene expression significantly increased 6 and 18 hours after PE [cytokine-induced neutrophil chemoattractant-1 (CINC-1) 18-fold and 24-fold; cyclooxygenase-2 21-fold and 32-fold]. Eighteen hours after PE, there was significant upregulation of adhesion molecules (selectin E 18-fold; intercellular adhesion molecule 1 14-fold), influx of neutrophils (myeloperoxidase activity 21-fold), depressed RV function (RV peak systolic pressure = 24 ± 3 vs. 40 ± 1 mm Hg; maximum rate of pressure development = 444 ± 79 vs. 1533 ± 146; maximum rate of pressure decrease = -357 ± 50 vs. -651 ± 44), and release of cardiac troponin I (7.8 ± 1.9 ng/mL) compared with vehicle. Ketorolac (10 mg/kg, intraperitoneally) significantly reduced expression of CINC-1, cyclooxygenase-2, selectin E, and intercellular adhesion molecule 1, lowered neutrophil influx, improved RV function (RV peak systolic pressure was 34 ± 3 mm Hg; maximum rate of pressure development = 1288 ± 146; maximum rate of pressure decrease = -611 ± 92), and marginally reduced cardiac troponin I release (P < 0.07) compared with PE alone. Ketorolac reduced CINC-1 stimulated chemotaxis of isolated neutrophils. PE converted cardiac tissue into a proinflammatory phenotype. Ketorolac reduced RV inflammatory genes, reduced neutrophil influx, and improved RV function in rat PE.",
keywords = "Cyclooxygenase, Inflammation, NSAID, Neutrophils, Pulmonary embolism, Right ventricle",
author = "Watts, {John A.} and Gellar, {Michael A.} and Stuart, {Lori K.} and Maria Obraztsova and Kline, {Jeffrey A.}",
year = "2009",
month = "9",
day = "1",
doi = "10.1097/FJC.0b013e3181b2b699",
language = "English (US)",
volume = "54",
pages = "246--252",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Proinflammatory events in right ventricular damage during pulmonary embolism

T2 - Effects of treatment with ketorolac in rats

AU - Watts, John A.

AU - Gellar, Michael A.

AU - Stuart, Lori K.

AU - Obraztsova, Maria

AU - Kline, Jeffrey A.

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Right ventricular (RV) damage contributes to poor clinical outcome after pulmonary embolism (PE). Our studies show that neutrophils contribute to RV dysfunction in rat PE. Present studies examine effects of the nonsteroidal anti-inflammatory drug, ketorolac, upon RV inflammation and dysfunction. RV inflammatory gene expression significantly increased 6 and 18 hours after PE [cytokine-induced neutrophil chemoattractant-1 (CINC-1) 18-fold and 24-fold; cyclooxygenase-2 21-fold and 32-fold]. Eighteen hours after PE, there was significant upregulation of adhesion molecules (selectin E 18-fold; intercellular adhesion molecule 1 14-fold), influx of neutrophils (myeloperoxidase activity 21-fold), depressed RV function (RV peak systolic pressure = 24 ± 3 vs. 40 ± 1 mm Hg; maximum rate of pressure development = 444 ± 79 vs. 1533 ± 146; maximum rate of pressure decrease = -357 ± 50 vs. -651 ± 44), and release of cardiac troponin I (7.8 ± 1.9 ng/mL) compared with vehicle. Ketorolac (10 mg/kg, intraperitoneally) significantly reduced expression of CINC-1, cyclooxygenase-2, selectin E, and intercellular adhesion molecule 1, lowered neutrophil influx, improved RV function (RV peak systolic pressure was 34 ± 3 mm Hg; maximum rate of pressure development = 1288 ± 146; maximum rate of pressure decrease = -611 ± 92), and marginally reduced cardiac troponin I release (P < 0.07) compared with PE alone. Ketorolac reduced CINC-1 stimulated chemotaxis of isolated neutrophils. PE converted cardiac tissue into a proinflammatory phenotype. Ketorolac reduced RV inflammatory genes, reduced neutrophil influx, and improved RV function in rat PE.

AB - Right ventricular (RV) damage contributes to poor clinical outcome after pulmonary embolism (PE). Our studies show that neutrophils contribute to RV dysfunction in rat PE. Present studies examine effects of the nonsteroidal anti-inflammatory drug, ketorolac, upon RV inflammation and dysfunction. RV inflammatory gene expression significantly increased 6 and 18 hours after PE [cytokine-induced neutrophil chemoattractant-1 (CINC-1) 18-fold and 24-fold; cyclooxygenase-2 21-fold and 32-fold]. Eighteen hours after PE, there was significant upregulation of adhesion molecules (selectin E 18-fold; intercellular adhesion molecule 1 14-fold), influx of neutrophils (myeloperoxidase activity 21-fold), depressed RV function (RV peak systolic pressure = 24 ± 3 vs. 40 ± 1 mm Hg; maximum rate of pressure development = 444 ± 79 vs. 1533 ± 146; maximum rate of pressure decrease = -357 ± 50 vs. -651 ± 44), and release of cardiac troponin I (7.8 ± 1.9 ng/mL) compared with vehicle. Ketorolac (10 mg/kg, intraperitoneally) significantly reduced expression of CINC-1, cyclooxygenase-2, selectin E, and intercellular adhesion molecule 1, lowered neutrophil influx, improved RV function (RV peak systolic pressure was 34 ± 3 mm Hg; maximum rate of pressure development = 1288 ± 146; maximum rate of pressure decrease = -611 ± 92), and marginally reduced cardiac troponin I release (P < 0.07) compared with PE alone. Ketorolac reduced CINC-1 stimulated chemotaxis of isolated neutrophils. PE converted cardiac tissue into a proinflammatory phenotype. Ketorolac reduced RV inflammatory genes, reduced neutrophil influx, and improved RV function in rat PE.

KW - Cyclooxygenase

KW - Inflammation

KW - NSAID

KW - Neutrophils

KW - Pulmonary embolism

KW - Right ventricle

UR - http://www.scopus.com/inward/record.url?scp=70349731954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349731954&partnerID=8YFLogxK

U2 - 10.1097/FJC.0b013e3181b2b699

DO - 10.1097/FJC.0b013e3181b2b699

M3 - Article

C2 - 19620882

AN - SCOPUS:70349731954

VL - 54

SP - 246

EP - 252

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 3

ER -